Those include two HER2+ breast cancer patient cohorts treated with chemotherapy plus Trastuzumab [47,52], a BRCA+ pancreatic cancer cohort treated with PARP inhibitors (Olaparib or Veliparib), a mixed indication cohort of Lung, Cervical and Head & Neck patients treated with Bintrafusp alfa [53], a bi-specific antibody that targets TGFB and PDL1, and finally, an ALK+ NSCLC cohort treated with ALK inhibitors (Alectinib or Crizotinib). This evidence concerns the gene CD274 and breast carcinoma.